HRP20190219T1 - Spojevi za tretman pretilosti i postupci za njihovu uporabu - Google Patents

Spojevi za tretman pretilosti i postupci za njihovu uporabu

Info

Publication number
HRP20190219T1
HRP20190219T1 HRP20190219TT HRP20190219T HRP20190219T1 HR P20190219 T1 HRP20190219 T1 HR P20190219T1 HR P20190219T T HRP20190219T T HR P20190219TT HR P20190219 T HRP20190219 T HR P20190219T HR P20190219 T1 HRP20190219 T1 HR P20190219T1
Authority
HR
Croatia
Prior art keywords
procedures
compounds
adult treatment
adult
treatment
Prior art date
Application number
HRP20190219TT
Other languages
English (en)
Croatian (hr)
Inventor
Umut Ozcan
Original Assignee
The Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children's Medical Center Corporation filed Critical The Children's Medical Center Corporation
Publication of HRP20190219T1 publication Critical patent/HRP20190219T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20190219TT 2013-11-26 2014-11-25 Spojevi za tretman pretilosti i postupci za njihovu uporabu HRP20190219T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908998P 2013-11-26 2013-11-26
PCT/US2014/067393 WO2015081093A1 (en) 2013-11-26 2014-11-25 Compounds for the treatment of obesity and methods of use thereof
EP14816018.7A EP3074033B1 (en) 2013-11-26 2014-11-25 Compounds for the treatment of obesity and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20190219T1 true HRP20190219T1 (hr) 2019-03-22

Family

ID=52134396

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190219TT HRP20190219T1 (hr) 2013-11-26 2014-11-25 Spojevi za tretman pretilosti i postupci za njihovu uporabu

Country Status (18)

Country Link
US (1) US20160375039A1 (cg-RX-API-DMAC7.html)
EP (1) EP3074033B1 (cg-RX-API-DMAC7.html)
JP (2) JP6672157B2 (cg-RX-API-DMAC7.html)
AU (2) AU2014354831B2 (cg-RX-API-DMAC7.html)
CA (1) CA2931826C (cg-RX-API-DMAC7.html)
CY (1) CY1122551T1 (cg-RX-API-DMAC7.html)
DK (1) DK3074033T3 (cg-RX-API-DMAC7.html)
ES (1) ES2709976T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190219T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042196T2 (cg-RX-API-DMAC7.html)
LT (1) LT3074033T (cg-RX-API-DMAC7.html)
PL (1) PL3074033T3 (cg-RX-API-DMAC7.html)
PT (1) PT3074033T (cg-RX-API-DMAC7.html)
RS (1) RS58422B1 (cg-RX-API-DMAC7.html)
SI (1) SI3074033T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900064T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901299T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015081093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN106008657B (zh) * 2016-05-20 2017-11-21 天津中医药大学 苦蘵苦素i及提取方法及用途
IT201800005336A1 (it) * 2018-05-14 2019-11-14 Composizioni per uso nel trattamento dell’obesità
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides
CN113599502A (zh) * 2021-07-22 2021-11-05 廖儒佳 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
CA2223433C (en) 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
CZ416797A3 (cs) 1995-06-30 1998-06-17 Eli Lilly And Company Použití leptinu nebo leptonových mimetik pro výrobu léčiv pro léčení nebo prevenci diabetes mellitus a kompozice s jeho obsahem
DK0865294T3 (da) 1995-08-17 2004-06-28 Amgen Inc Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
NZ512083A (en) 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
CA2258504A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
JP2001501177A (ja) 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Obタンパク質受容体をアップレギュレートすることによりobタンパク質に対する個体の感受性を増加させる方法
HUP9904023A3 (en) 1996-09-20 2002-01-28 Hoechst Ag Use of leptin antagonists for treating insulin resistance in type ii diabetes
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
RS49927B (sr) 1996-12-20 2008-09-29 Amgen Inc., Preparati ob fuzionog proteina i postupci
CN1202862C (zh) 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
KR20010013414A (ko) 1997-06-06 2001-02-26 피터 기딩스 당뇨병의 치료를 위한 렙틴 길항제의 용도
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
ATE280588T1 (de) 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PT1151102E (pt) 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
JP4585186B2 (ja) * 2003-07-31 2010-11-24 杏林製薬株式会社 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
PT2040755E (pt) * 2006-06-23 2011-07-08 Esteve Labor Dr Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
WO2010030395A2 (en) * 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
WO2012106393A2 (en) * 2011-02-01 2012-08-09 University Of Kansas Withanolide isolated from physalis longifolia and analogs and methods of use thereof

Also Published As

Publication number Publication date
US20160375039A1 (en) 2016-12-29
JP2016537431A (ja) 2016-12-01
JP6672157B2 (ja) 2020-03-25
AU2018200517A1 (en) 2018-02-15
PT3074033T (pt) 2019-02-08
WO2015081093A1 (en) 2015-06-04
LT3074033T (lt) 2019-02-25
TR201901299T4 (tr) 2019-02-21
EP3074033A1 (en) 2016-10-05
CA2931826C (en) 2021-11-16
AU2018200517B2 (en) 2019-12-19
JP2020059744A (ja) 2020-04-16
HUE042196T2 (hu) 2019-06-28
CY1122551T1 (el) 2021-01-27
DK3074033T3 (en) 2019-02-11
SI3074033T1 (sl) 2019-03-29
ES2709976T3 (es) 2019-04-22
EP3074033B1 (en) 2018-11-07
PL3074033T3 (pl) 2019-08-30
CA2931826A1 (en) 2015-06-04
AU2014354831B2 (en) 2017-10-26
AU2014354831A1 (en) 2016-06-09
RS58422B1 (sr) 2019-04-30
SMT201900064T1 (it) 2019-02-28

Similar Documents

Publication Publication Date Title
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
SI3033086T1 (sl) Kombinirana terapija za zdravljenje raka
DK2968208T3 (da) Behandling af kataplexi
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
HRP20182138T1 (hr) Modificirani serpini za liječenje poremećaja s krvarenjem
HRP20180478T1 (hr) Crenolanib za liječenje flt3 mutiranih proliferativnih poremećaja
LT3007726T (lt) Tautopatijos gydymo būdai
SI2991633T1 (sl) Terapija za bakteriofagi
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
HRP20181122T1 (hr) Postupak za pripremu jopamidola
LT2981303T (lt) Užpildo kompozicija lipoatrofijos gydymui
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
HRP20181980T1 (hr) Ciklezonid za liječenje dišnih puteva kod konja
BR112016008387A2 (pt) Conjunto de absorvente descartável, e, artigo absorvente
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
PL2948137T3 (pl) Sposoby leczenia zwłóknienia i nowotworów
EP2839068A4 (en) Clothes treatment apparatus
EP2994184C0 (en) An unravelable catheter
DK2976101T3 (da) Behandlingsfremgangsmåde
HRP20181913T1 (hr) Sastav za liječenje upale bolesti zglobova
DK3041506T3 (da) Behandlingsfremgangsmåde